Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 4, keine Gesamtzahl für „venetoclax“
Suchtreffer
Begriffe & Kennungen
Venclyxto · 4.5 · For patients requiring concomitant use of venetoclax with strong CYP3A inhibitors (e.g., itraconazole, ketocon
Eintrag öffnenVenclyxto · 4.5 · If a statin (OATP substrate) is used concomitantly with venetoclax, close monitoring of statin-related toxicit
Eintrag öffnenVenclyxto · 4.5 · In studies of ibrutinib (420 mg) in combination with venetoclax (400 mg) in CLL patients, an increase in venet
Eintrag öffnenVenclyxto · 4.5 · Venetoclax is a P-gp, BCRP and OATP1B1 inhibitor in vitro. In a drug-drug interaction study, administration of
Eintrag öffnenVenclyxto · 4.5 · Venetoclax is a substrate for P-gp and BCRP. Co-administration of a 600 mg single dose of rifampicin, a P-gp i
Eintrag öffnenVenclyxto · 4.5 · Venetoclax is predominantly metabolised by CYP3A.
Eintrag öffnenVenclyxto · 4.8 · 14 The most frequently reported serious adverse reactions (≥2%) in patients receiving venetoclax in combinatio
Eintrag öffnenVenclyxto · 4.8 · 15 Table 8: Adverse drug reactions reported in patients with CLL treated with venetoclax
Eintrag öffnenVenclyxto · 4.8 · 16 Table 9: Adverse drug reactions reported in patients with AML treated with venetoclax
Eintrag öffnenVenclyxto · 4.8 · 20 percent experienced dose interruption, 4% had dose reduction and 1 patient (0.3%) discontinued venetoclax d
Eintrag öffnenVenclyxto · 4.8 · AMPLIFY When venetoclax is administered in combination with acalabrutinib with or without obinutuzumab, refer
Eintrag öffnenVenclyxto · 4.8 · Discontinuations due to adverse reactions occurred in 16% of patients treated with venetoclax in combination w
Eintrag öffnenVenclyxto · 4.8 · Dosage reductions due to adverse reactions occurred in 21% of patients treated with venetoclax in combination
Eintrag öffnenVenclyxto · 4.8 · In M14-358 study, no events of laboratory or clinical TLS were reported with venetoclax in combination with de
Eintrag öffnenVenclyxto · 4.8 · In the CLL14 study, neutropenia (all grades) was reported in 58% of patients in the venetoclax + obinutuzumab
Eintrag öffnenVenclyxto · 4.8 · In the MURANO study, neutropenia (all grades) was reported in 61% of patients in the venetoclax + rituximab ar
Eintrag öffnenVenclyxto · 4.8 · In the VIALE-A study, discontinuations of venetoclax due to adverse reactions occurred in 24% of patients trea
Eintrag öffnenVenclyxto · 4.8 · In the randomised, phase 3 study (VIALE-A) with venetoclax in combination with azacitidine the incidence of TL
Eintrag öffnenVenclyxto · 4.8 · In the venetoclax + ibrutinib arm in the GLOW study, all-grade neutropenia/neutrophil count decreased was repo
Eintrag öffnenVenclyxto · 4.8 · Paediatric population The safety profile of venetoclax in paediatric patients is based on data from an open-la
Eintrag öffnen